Our coverage on the latest scoop
News and Media Releases
Breaking Through the Stigma
By David Harder, ATMA co-founder and co-CEO I met with...
READ MORE
How To Change Your Mind
Upon the release of his book How to Change Your...
READ MORE
Clinical Trials and Psychedelics
Clinical trials are the standard way to evaluate the safety...
READ MORE
Psilocybin-assisted Therapy: The Safe and Effective Alternative
Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various...
READ MORE
Magic Mushrooms (Psilocybin) and End-of-life
End-of-life distress has been an ongoing focus for psilocybin clinical...
READ MORE
Is Training in Psychedelics Worth It?
Let’s start with a brief review of psychedelics, including what...
READ MORE
ATMA Sponsors Catalyst Summit 2022 on Psychedelic Medicine
ATMA to Sponsor Catalyst Summit 2022, May 20-22
READ MORE
ATMA Submits Phase II Clinical Trial Application, Assessing Psilocybin Efficacy in Healthcare Professionals Suffering From COVID-19-Related Mental Wellness Challenges.
CALGARY, AB, May 10, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company...
READ MORE
Filament Health and ATMA Journey Centers Announce Licensing Agreement
ATMA will use Filament’s proprietary botanical drug candidate for clinical...
READ MORE
Health Canada Provides a No-Objection Letter to Atma Journey Centers: A Clinical Trial Assessing Psilocybin Safety and Exploring Psychological Outcome in Licensed Medical Practitioners
CALGARY, AB, Jan. 7, 2022 /CNW/ – ATMA Journey Centers...
READ MORE